triple glp-1/gip/glucagon receptor agonist LY3437943, a novel glucagon, GIP, and GLP-1 for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism Why Retatrutide is different 👇

Practical help in 4 modules Module 1 Webinar Now available On Demand Understanding the issues around the GLP-1 RA shortage Understanding the impact of the current GLP-1 RA shortage Making sense of the guidance published Identifying and prioritising those affected Practical resources to support clinicians Plus downloadable guides: Module 2 Webinar Now available On Demand Tackling the GLP-1 RA shortage in clinical practice: A consultation guide Applying national guidance in practice Promoting patient-centred discussion Identifying appropriate alternatives to GLP-1 RAs Working through practical case examples Plus downloadable guides: Module 3 Common patient scenarios Now available on demand Module 4 Webinar Where are we now

Which causes more weight loss: phentermine or GLP-1 agonists

GLP-1 receptor agonists and GLP-1/GIP combination therapies have become foundational treatments for type 2 diabetes and obesity

Nausea, vomiting, and diarrhea are among the most common adverse effects of GLP-1 receptor agonists, with frequencies varying by product and dose